Canada markets closed

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3300+0.0349 (+11.83%)
At close: 3:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2951
Open0.3101
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3100 - 0.3300
52 Week Range0.0680 - 0.4660
Volume14,190
Avg. Volume16,076
Market Cap11.994M
Beta (5Y Monthly)0.77
PE Ratio (TTM)N/A
EPS (TTM)-0.0480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
    ACCESSWIRE

    RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map

    Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimizationVANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company") is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ("UBC") that enables the second stage of its cell marker research.

  • RepliCel Announces Record Year in Patents Granted
    ACCESSWIRE

    RepliCel Announces Record Year in Patents Granted

    Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration TechnologiesVANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.

  • RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
    ACCESSWIRE

    RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)

    Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in JapanVANCOUVER, BC / ACCESSWIRE / May 3, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Tsukasa Kumai, one of Japan's leading sports medicine clinicians, has agreed to be RepliCel's clinical advisor for the development and commercialization of its tendon regeneration product (RCT-01) in Japan.